SAN BEDA UNIVERSITY

COLLEGE OF NURSING

PATIENT-CENTERED DRUG STUDY/ ANALYSIS

STUDENT’S INFORMATION
Name: Alessandra Dominique O. Mariano__________________________________ Year and Section: _3 - ACN______
Group: 2B____ Agency/ Area: _Emergency Room___________________________________________ Shift: ________
Inclusive Dates of Rotation: May 5, 2021______________ Clinical Instructor: Elizabeth D. Cruz_________________

PATIENT’S INFORMATION
Name of Patient: Px D.M.G.________________________________________________ Age: 57 years old__ Sex: Male_
Chief Complaint: _Chest Pain with nausea with some heartburn____________________________________________
Diagnosis: _ Impaired Tissue Perfusion r/t Decreased Cardiac Output ________________________________________

DRUG INFORMATION
Drug Classification: Vasodilator/Nitrate_____________ Generic Name: Nitroglycerin_______________________
Dosage: 0.4 mg SL q5min for up to 3 doses__________ Brand Name: Anginine, Nitradisc____________________
Route of Administration: Sublingual__________________

MODE/ MECHANISM OF ACTION

Works by relaxation of smooth muscle, producing a vasodilator effect on the peripheral veins and arteries with more
prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-
diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic
regions.

INDICATION
Nitroglycerin is indicated for the acute relief of an attack
or acute prophylaxis of angina pectoris due to coronary
artery disease.
CONTRAINDICATION
Contraindicated to patients hypersensitive to nitrates and
those with early MI, severe anemia, increased intracranial
pressure, orthostatic hypotension, allergy to adhesives,
and to patients with hypovolemia, hypotension.

SIDE EFFECT AND ADVERSE REACTION

 Fast, slow, pounding, or uneven heart rate;
 Blurred vision or dry mouth;
 Feeling light-headed, nausea, vomiting, sweating, pale skin fainting, or;
 Fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
 Mild burning or tingling with the tablet in mouth;
 Warmth, redness, or tingly feeling under your skin, or;
 Feeling weak or dizzy.

SBU.CON.RLE.2017.11.1 Page 1 of 2
 DRUG INTERACTIONS (Drug-Drug, Drug-Food, Drug-Laboratories)
 PDE-5-Inhibitors And sGC-Stimulators - NITROSTAT is contraindicated in patients who are using a selective
inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). PDE-5-
Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive
effects of organic nitrates.
 Ergotamine - Oral administration of nitroglycerin markedly decreases the first-pass metabolism of
dihydroergotamine and subsequently increases its oral bioavailability. Ergotamine is known to precipitate
angina pectoris. Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related
drugs or be monitored for symptoms of ergotism if this is not possible.

NURSING CONSIDERATIONS/ HEALTH TEACHINGS

 Inform prescriber of all prescriptions, OTC medications, or herbal products you are taking, and any allergies
you have.
 Do not take any new medication during therapy unless approved by prescriber. Take as per directed.
 Do not change brands without consulting prescriber. Do not discontinue abruptly.
 Keep medication in original container, tightly closed. If chest pain is unresolved in 15 minutes, seek
emergency medical help at once. Daily use may cause dizziness or lightheadedness.

Prepared by: Evaluated by:

Alessandra Dominique O. Mariano Elizabeth D. Cruz

Student Nurse’s Signature over Printed Name Clinical Instructor’s Signature over Printed Name

DATE: May 5, 2021 DATE: May 5, 2021

SBU.CON.RLE.2017.11.1 Page 2 of 2